HER2 targeting therapy and SORLA (IMAGE)

University of Turku

HER2 targeting therapy and SORLA

Caption

SORLA removal sensitizes metastatic breast cancer cells to HER2 targeting therapy. Aggressive metastatic breast cancer cells growing in the brains of fish embryos. The tumors are resistant to anti-HER2 therapy alone but sensitive when anti-HER2 therapy is combined with SORLA depletion.

Credit

Ilkka Paatero from Turku Bioscience

Usage Restrictions

Please attribute the image to Ilkka Paatero

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.